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Objectives: The aim of this work was to develop and validate an HPLC method for gentamicin quantifi-
cation in different types of biological samples such as animal tissues and cellular material and also in
pharmaceuticals.
Methods: Poly(lactide-co-glycolide) microparticles (MP) of gentamicin (PLGA 502H MP), THP-1 cells, and
plasmaand tissue samples ofmice treatedwith the antibiotic either free or loaded intoPLGA502HMPwere
processed by a simple preparation procedure, subjected to chromatography on a reversed-phase column
and measured by mass spectrometry detection. The developed method was compared with bioassay and
fluorimetric assay methods previously used for gentamicin determination.
Results: The HPLCmethodwas linear over the ranges 40–800 ng/mL and 0.1–100mg/mL and showed good
accuracy (average accuracy < 5.59%) and reproducibility (CV < 6.13%). Encapsulation of gentamicin in
PLGA 502H MP was determined by the three methods. Good correlation was observed between bioassay
(reference method) and HPLC. Extra- and intracellular in vitro antibiotic accumulation was determined by
bioassay and chromatography. Both methods gave similar extracellular concentrations but the HPLC-MS
technique demonstrated an improved accuracy (5.59% versus 14%) and precision (6.13% versus 15%)
compared with bioassay. However, only the HPLC-MS method was sensitive enough to detect the drug,
intracellularly and in tissues.
Conclusions: All these data favour the use of chromatography-mass spectrometry as a versatile technique
not only suitable for gentamicin quantification loaded in drug delivery systems, but also sensitive and
specific enough for in vivo and intracellular studies.
Keywords: HPLC-MS, bioassay, fluorimetric assay, cellular quantification, biological matrices, drug delivery
systems, PLGA
Introduction
Gentamicin is one of the most commonly used antibiotics world-
wide in the treatment of many susceptible Gram-negative bac-
terial infections. However, it induces nephrotoxicity and
ototoxicity and has a poor cellular penetration that limits its
activity against intracellular pathogens,1 such as Brucella. To
overcome this problem, polymeric drug delivery systems contain-
ing gentamicin have been developed with the aim of permitting
the antibiotic to reach therapeutic concentrations intracellularly.
Therefore, gentamicin needs to be quantified for drug delivery
system characterization, intracellular distribution studies, free or
vehicular, and for pharmacokinetic assays. For all these studies
the most suitable quantification method must be chosen. It should
have a high sensitivity, specificity and reproducibility, and should
be capable of measuring a wide range of concentrations of this
antibiotic, besides its low cost.
Many techniques have been developed for this purpose. Deriv-
atization and further fluorimetric2,3 or colorimetric assays4 have
been used for its quantification in solutions. Although they are
easy to perform and inexpensive, the sensitivity of these tech-
niques is too low (0.39 mg/mL for gentamicin derivatization with
ninhydrin4) or 1 mg/mL when reacted with o-phthalaldehyde5 for
intracellular concentration and pharmacokinetic studies. The
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bioassay is the method prescribed by British, European and US
pharmacopoeias for the determination of gentamicin and the
other aminoglycosides in pharmaceuticals. Nevertheless, this
technique has many important drawbacks. It is inaccurate,6
lacks specificity because other antibacterial substances present
in biological samples can interfere in bacterial inhibition and
also shows low sensitivity with detection limits around 0.1 mg/
mL, which hinder gentamicin quantification in pharmacokinetic
or cellular internalization studies.7
Automated assay procedures, such as radioimmunoassay
(RIA), enzyme immunoassays (EIA) (heterogeneous or homogen-
eous), fluoroimmunoassay, direct chemiluminescence immunoas-
say and nephelometric and turbidimetric assay,6 have been
developed for gentamicin quantification in serological samples.
They are very sensitive, specific, require only small sample
volume and can be performed by commercially available kits.
However, these automated assays show a series of drawbacks: the
requirement for expensive b-counting equipment, provision for
use and disposal of radioactive materials, a labour-intensive
procedure8 and skilled personnel.
In previous work performed to date in our laboratory, the
chosen technique was derivatization with o-phthalaldehyde and
fluorimetric assay,9 which was performed for gentamicin encap-
sulation in a drug delivery system. Its drawbacks, as described
above, are the low specificity and the relatively low sensitivity.
The aim of the present work was to develop a technique suitable
for gentamicin quantification in cellular internalization studies,
which can be also applied for pharmacokinetic studies and for the
characterization of particulated systems (gentamicin-loading,
antibiotic in vitro release). A more sensitive method was needed,
as long as low concentrations could be found in biological sam-
ples, and, at the same time, minimal interferences were desirable
with proteins and other components of samples. HPLC is the
technique that offers the highest resolution and best degree of
specificity. When coupled with mass spectrometry, it becomes
the most powerful method for the confirmation of antibiotic
residues in food,6 with quantification limits in the order of nano-
grams. The technique developed in the present work is a sensitive
analytical method based on a highly specific and selective chro-
matographic separation and mass spectrometry detection after
electrospray ionization (HPLC-ESI-MS). Furthermore, comparis-
ons with fluorimetric assay after drug derivatization (the tech-
nique used up to now) and bioassay (as reference method) were
performed.
Materials and methods
Materials
Gentamicin sulphate, b-mercaptoethanol, Trypan Blue and phorbol
12-myristate 13-acetate (PMA) were from Sigma-Aldrich Co.
(St Louis, MO, USA).
The poly(D, L-lactide-co-glycolide) (PLGA) copolymer with free
carboxyl end group: 13.7 kDa, PLGA 50:50 (Resomer RG 502H)
was provided by Boehringer-Ingelheim (Ingelheim, Germany). Ethyl
acetate, monopotassium phosphate, sodium dibasic phosphate,
diethyl ether, boric acid, ethanol, NaOH, trichloroacetic acid and
dichloromethane were from Panreac (Barcelona, Spain). Poly(vinyl-
alcohol) (PVA, MW 15 000) was purchased from BDH Supplies
(Poole, UK). Pentafluoropropionic acid (PFPA) was from Fluka Che-
mie (Buchs, Switzerland). Tobramycin (internal standard), procured
as Tobra-Gobens (the brand name of the product registered for
clinical use in Spain), was purchased from Normon (Madrid,
Spain). Methanol (Lichrosolv) and o-phthalaldehyde were from
Merck (Darmstadt, Germany). Mueller–Hinton broth was purchased
from DIFCO Laboratories (Detroit, MI, USA) and the American
Bacteriologic Agar from Pronadisa, Hispanlab (Madrid, Spain). Ster-
ile swabs (Invasive sterile Eurotubo collection swabs) were from
I.A.S.A. (Rubi, Spain), and sterile cellulose discs were purchased
from BD (Franklin Lakes, NJ, USA). Staphylococcus aureus 25923
was obtained from the American Type Culture Collection (ATCC).
Finally, for cell culture, THP-1 cells, a human myelomonocytic
cell line displaying macrophage-like activity,10 were kindly provided
by Professor D. Raoult of the Unite des Rickettsies, Universite´ de la
Mediterrane´e, Marseille, France. RPMI cell culture medium and
L-glutamine were purchased from Gibco (Invitrogen, Carlsbad,
CA, USA). Fetal calf serum was from Biochrom AG (Berlin,
Germany).
Preparation and physicochemical characterization
of gentamicin microparticles
Poly(lactide-co-glycolide) microparticles (MP), made of PLGA 502H,
and containing gentamicin, were prepared by a water-oil-water
solvent evaporation technique.11 Briefly, the antibiotic (10 mg)
dissolved in 0.5% PVA in phosphate buffer, pH 6.0, and 200 mg
of polymer dissolved in dichloromethane were mixed by ultrason-
ication (Branson sonifier 450, Branson Ultrasonics corp., Danbury,
CT, USA) under cooling for 1 min, to form a W1/O emulsion. This
inner emulsion was added to 2 mL of 1% PVA (W2) and homo-
genized again by ultrasonication. The resulting (W1/O)W2 emulsion
was poured into 50 mL of 0.2% PVA and continuously stirred for, at
least, 3 h at room temperature to allow solvent evaporation and MP
formation. After preparation, the microspheres were isolated by
centrifugation (7000 g, 5 min), washed with ultra pure water and
freeze-dried.
MP diameter was determined by laser light diffraction
(Mastersizer, Malvern Instruments, Worcestershire, UK). The aver-
age particle size was expressed as the volume mean diameter in
micrometres. The zeta potential of the MP dispersed in ultra pure
water was performed using a Zetamaster system (Malvern Instru-
ments, Worcestershire, UK).
The final formulation containing gentamicin presented a mean
particle diameter of 1.8 mm and zeta potential of –21.5 mV.
Antibiotic extraction from particles
Antibiotic extraction from MP was performed as follows:
(i) Dissolving the loaded microspheres in 1 mL of dichloromethane
and extracting the drug three times with 2 mL of phosphate buffer,
pH 6.0.
(ii) Dispersing the microspheres in 1 mL of 0.1 M NaOH.
In both cases, samples were centrifuged and gentamicin was quan-
tified in the supernatant.
Determination of cellular antibiotic accumulation
THP-1 cells (human myelomonocytic cell line displaying macro-
phage-like activity)10 were maintained in RPMI medium supplemen-
ted with 10% heat inactivated fetal calf serum and 2 mM L-glutamine
in a 5% CO2 atmosphere. During culture, cell density did not exceed
1 · 106 cells/mL. A volume of 500 mL of THP-1 monocytes
was plated into wells (1 · 106 cells/mL) with 10 ng/mL PMA and
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incubated for 48 h12 in order to allow differentiation into macro-
phages. Then, wells were washed once, and different concentrations
of gentamicin were added in fresh medium and incubated for 24 h.
Afterwards, extracellular fractions were collected; cells were washed
five times to eliminate the antibiotic outside the cells and detached
from wells with 500 mL of 0.05% trypsin-EDTA. Finally, three
cycles of freeze–thawing (in liquid nitrogen and water bath at
45C) were performed to assure complete cell lysis, and intracellular
content was collected after centrifugation (1000 g, 10 min) to remove
cellular debris. All samples were then frozen (–20C) until analysis.
For the present study, only HPLC and bioassay were used for gen-
tamicin quantification. The fluorimetric assay could not be used
because of the interference in the analysis by amino acids present
in RPMI.
Quantification of gentamicin concentrations
in tissue samples
Tissue concentrations of gentamicin administered either free or
loaded into PLGA 502H MP were determined in mice. Female
BALB/c mice of 20 – 1 g were supplied by Harlan Iterfauna Ibe´rica
(Barcelona, Spain). The experiments were performed in compliance
with the regulations of the responsible committee of the University of
Navarra in line with the European legislation on animal experiments
(86/609/EU).
Mice (n = 3) received one dose of 30 mg (1.5 mg/kg) of the
antibiotic intravenously, either free or loaded into PLGA particles.
After the administration of the free antibiotic, concentrations were
undetectable. Consequently, three doses every 2.5 h of 40 mg/kg of
free gentamicin were used. At different times, animals were anaes-
thetized, bled by retro-orbital puncture and sacrificed by cervical
dislocation and livers were extracted. Once diluted in saline solution,
organs were homogenized, centrifuged (10 000 g, 15 min) and super-
natants collected. Proteins were precipitated by 1% trichloroacetic
acid and samples were analysed by HPLC as described below.
Gentamicin quantification methods
HPLC-mass spectrometry. The apparatus used for the HPLC analysis
was a Model 1100 Series LC coupled with an atmospheric pressure
(AP)-electrospray ionization (ESI) mass spectrometer (HP 1100 with
MSD VL, Waldbronn, Germany). A Hewlett-Packard computer using
the ChemStation G2171 AA program was used for data acquisition
and analysis.
Separation was carried out at 50C on a reversed-phase
Lichrospher C8 60 RP column, of 250 mm · 4 mm, purchased
from Merck (Darmstadt, Germany). The chosen flow rate was
0.5 mL/min. Ionization was performed in positive Selected Ion
Monitoring (SIM) mode; the ions m/z values were 468.20 for
gentamicin and 478.30 for tobramycin. Capillary voltage was
4000 V and fragmentator voltage was 140 V. Temperature was
350C, and the drying gas (12 L/min) and the nebulizer gas (60
psi) were both nitrogen. As mobile phase, a linear gradient of
PFPA (20 mM in ultrapure water) and methanol was used. For
the chromatographic quantification of gentamicin, all samples,
from MP extraction or from cell studies, were processed equally
(diluted with the same volume of a solution with a proportion of
PFPA:methanol 1:1) and either 1 or 25 mL was injected onto the
HPLC column, maintaining the injected tobramycin amount constant.
Bioassay. Gentamicin was assayed by a standard disc-diffusion tech-
nique. Two or three isolated colonies of S. aureus were inoculated in
fresh Mueller–Hinton broth and incubated at 37C until reaching an
absorbance at 590 nm of 0.125 (108 cfu/mL). A dilution of this
culture (105 cfu/mL) was used to inoculate Mueller–Hinton agar
plates for confluent growth of bacteria. Running in parallel, 20 mL
of different standard concentrations of gentamicin and samples were
added to cellulose discs and incubated for 5 h at 37C. The discs
were placed on the inoculated Mueller–Hinton agar plates and incub-
ated for 24 h at 37C. Finally, inhibition diameters were measured
and the unknown concentrations were determined extrapolating the
diameter values in the standard exponential curve.
Derivatization and fluorimetric assay. Standard concentrations of
gentamicin were prepared by serial dilutions in boric acid 0.4 M,
pH 9.7, and added to a 96-well microplate (TPP, Trasadingen,
Switzerland). Samples were also diluted, when needed, in boric
acid. Then, fluorimetric assay solution [0.04% o-phthalaldehyde,
0.1% (v/v) diethyl ether, 0.2% (v/v) b-mercaptoethanol in boric
acid] was added to the standard solutions. Fluorescence was meas-
ured, immediately, in a Tecan GENios fluorimeter (Tecan Group Ltd,
Maennedorf, Switzerland) (excitation 340 nm, emission 450 nm) and
sample concentrations were calculated by means of the standard
curve.5
Statistics
For determination of known concentrations of gentamicin by the
three techniques, linear regression was performed by using standard
techniques at four antibiotic concentrations, with three different sam-
ples measured at each concentration level.
In the case of antibiotic quantification from MP, since the three
methods were compared, analysis of variance (ANOVA) was per-
formed and Tukey was used as the post-hoc test. For intracellular
accumulation study, Student’s t-test was performed because HPLC
and bioassay were compared. In all cases, bioassay was used as the
reference method. For all statistical analysis, SPSS program, version
11.0 (SPSS Inc., Chicago, USA), was used.
Results
Determination of gentamicin by HPLC
Gentamicin and tobramycin were found to have retention times of
9.42 and 8.66 min, respectively. Typical chromatograms of
a pharmaceutical formulation, cell extracts and mice liver are
shown in Figure 1 (a–c). Good separation was obtained from
the endogenous background, and area peak values were used
for antibiotic quantification. Standard curves were obtained at
two different ranges of concentration: for gentamicin extraction
from MP and for extracellular gentamicin concentrations, 1 mL
was injected and 100, 50, 25, 12.5, 6.25, 3.125, 1 and 0.1 mg/mL
standards were used, and for tissue and intracellular antibiotic
quantification, 25 mL was injected and samples with 8, 4, 2, 1,
0.5, 0.25, 0.125 and 0.04 mg/mL gentamicin concentrations were
used as standards. A linear relationship was found between the
peak area of gentamicin divided by the area of tobramycin (the
internal standard) and gentamicin concentration, giving standard
curves with r2 > 0.99. The method showed good levels of pre-
cision over the 2 years that it has been used, as demonstrated by
the relatively small CVs at each concentration (average CV for
interday variability <6.13%). Moreover, an excellent agreement
between the measured concentrations and the spiked concentra-
tions was obtained (average accuracy between 0.04 and 100 mg/
mL, concentration range <5.59%).
Determination of gentamicin by bioassay
The inhibition zones were clearly defined. The concentrations
used in the standard curve were 2000, 1000, 800, 660, 500, 250,
HPLC-MS gentamicin determination in different matrices
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125, 74, 62, 31 and 25 mg/mL and an exponential relationship
was found between the inhibition diameter and antibiotic con-
centration with r2 > 0.98. Intraday variability, defined as CV
assayed by 2000, 500, 125 and 62 mg/mL samples, averaged
<3%. The interday variability was determined by the average
CV of assays of five different days and the result was <15%.
The assay was sensitive above 25 mg/mL of the antibiotic (LOQ
value). To determine accuracy, two spiked controls of 500 and
100 mg/mL were assayed three times. The values obtained were
averaged and correlated to the expected value. An accuracy of
14% was obtained.
Determination of gentamicin by fluorescence assay
Concentrations of gentamicin chosen for the standard curve were
1000, 500, 250, 125, 62.5, 31.5, 15.62, 8.71 and 3.9 mg/mL.
Concentrations of the antibiotic and fluorescence emission
read at 450 nm presented a linear relationship with r2 < 0.98.
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Figure1. Typical chromatogramsof gentamicin (GEN) and tobramycinas internal standard (I.S.). (a) PLGA502HMP(gentamicinconcentration: 86mg/mL,1mLof
sample injected). (b) Intracellular gentamicin concentration after THP-1 cell incubation with 1250 mg/mL of the antibiotic (gentamicin concentration: 0.48 mg/mL,
25mLof sample injected). (c) Liver concentration of gentamicin at 7 days post-administration ofMPof PLGA502H (gentamicin concentration: 0.16mg/mL, 25mLof
sample injected). A colour version of this figure is available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/).
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Intraday variability was <12%, while interday variability reached
39%. The sensitivity of the assay was 3.9 mg/mL.
Comparison of HPLC, bioassay and fluorescence assays
Determination of gentamicin from microparticles. As shown in
Figure 2(a), gentamicin encapsulation obtained with fluorescence
assay always had lower results than the other two techniques.
Statistical differences were observed when comparing anti-
biotic derivatization with chromatography. This statistical signi-
ficance was higher when NaOH was used for extraction. On the
contrary, HPLC and bioassay presented no differences in drug
quantification.
Linear regressions were also performed to compare both
extraction techniques by the three methods. In concordance
with the results of Figure 2, the good correlation between
HPLC and bioassay was proved once more in all cases: for
dichloromethane and NaOH extraction, r2 values of 0.889 and
0.855, respectively, were obtained. On the contrary, poor correla-
tion was observed between fluorimetric assay and bioassay, with
r2 of 0.543 for dichloromethane extraction and even lower (r2 =
0.266) for NaOH.
Determination of cellular gentamicin accumulation. Gentamicin
intracellular and extracellular concentrations were determined by
HPLC and bioassay (Figure 2b). Antibiotic derivatization with
fluorimetric assay could not be used because of interference with
cell culture medium. Comparing the three methods, only chro-
matography was sensitive enough for detecting intracellular con-
centrations of the polar antibiotic, because only a small amount of
it crosses the cell membrane, while bioassay could only quantify
the extracellular gentamicin. For these latter concentrations of the
aminoglycoside, both techniques gave similar results, but the
deviations obtained with HPLC were smaller than those with
the microbiological assay (Figure 2b).
Finally, the scatterplot (Figure 3) showed the agreement
between HPLC and bioassay with an r2 of 0.954, indicating
the good correlation between the two methods.
Quantification of gentamicin concentrations in tissue samples.
HPLC proved to be the only technique sensitive enough to detect
gentamicin concentrations in animal organs after both gentami-
cin-free and gentamicin-encapsulated administration to mice. The
detection limit was similar to that observed for particle extraction
(0.02 mg/mL or 0.13 mg/g tissue) and lower than bioassay (25 mg/
mL). Comparison between HPLC and bioassay was not per-
formed since the levels of gentamicin detected in tissues were
below the quantification limit of bioassay. As shown in Figure 4,
the developed method allowed gentamicin quantification of both
the free and released antibiotic from MP. Free gentamicin
reached a concentration peak of 1.6 mg/g within the first day
post-administration and was cleared from hepatic tissue in 4 days.
On the contrary, microencapsulation led to a controlled release of
the drug as reflected in sustained concentrations detected in liver
(Figure 4), with measurable gentamicin levels for 27 days.
Discussion
The objective of the present study was to develop an HPLC assay
for gentamicin quantification that allows low concentration ana-
lysis in cell cultures and tissues as an alternative to the methods
employed today. With this purpose, the present work compares an
HPLC method with bioassay and derivatization with a fluorinated
compound for the determination of gentamicin levels in cell
internalization studies, pharmacokinetic studies and new micro-
size pharmaceutical preparations by direct injection.
Aminoglycosides are traditionally difficult to determine with
conventional HPLC because of the lack of strong chromophores
in the molecule structure and their highly polar characteristics.
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In general terms, derivatization with a fluorescent reagent, such
as fluorimetric assay, has been adopted as the methodology of
choice for the analysis of gentamicin.13 However, the use of this
methodology is not free from drawbacks. The fluorimetric assay
reagent is unstable and has to be prepared regularly, and an
incomplete derivatization of gentamicin was observed when cer-
tain samples (i.e. organic samples) were processed.14 This could
be an important source of error in the method, leading to the
underestimation of the aminoglycoside in the samples. This prob-
lem can be resolved by using more specific liquid chromato-
graphic/mass spectrometric (LC/MS) techniques.
Gentamicin and other aminoglycosides are extremely hydro-
philic, due to the high number of amino and hydroxyl moieties on
the carbon chain. Therefore, they are positively charged at the pH
range employed in reversed phase-liquid chromatography and are
not retained on conventional C-18 bonded silica columns without
an ion pair agent, but these agents can suppress ionization and
foul the LC/MS interface. The use of a fluorinated ion pair
reagent with moderate volatility, PFPA, and the application of
a step gradient with a decreasing concentration of the reagent
(gentamicin is therefore eluted into the mass spectrometer at
nearly zero PFPA concentration), allows this problem to be
resolved. In fact, the obtained limit of quantification (0.04 mg/
mL) was still more than adequate for monitoring the gentamicin
concentration in samples and was less than that of both the
bioassay (25 mg/mL) and fluorimetric assay (3.9 mg/mL).
Agar well-based microbiological methods are traditionally
employed to determine antimicrobial concentrations by measur-
ing graded responses to known concentrations of an antimicrobial
against a standard curve. Bioassays are easy to perform and do
not require special equipment. However, chromatographic assays
are preferred to biological assays for antibiotic quantification. In
our case, the major advantages of the HPLC method compared
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Figure 2. Comparison between methods. (a) Comparison of the three methods
for quantification of gentamicin (GEN) extraction from PLGA 50:50 MP by
NaOH and dichloromethane (DCM). (b) Comparison of HPLC and bioassay for
gentamicin intracellular (IC) and extracellular (EC) determination, after incub-
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Figure 3. Scatterplot of extracellular gentamicin concentrations determined by
bioassay and HPLC, after cell incubation with 1250, 500, 100 and 50 mg/mL.
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with the bioassay are its enhanced accuracy (5.59% versus 14%)
and precision (6.13% versus 15%).
We have compared the results of the HPLC analysis of the
samples with those obtained after microbiological assay and the
application of the derivatization procedure. Cell studies showed
an excellent correlation between the gentamicin concentrations
measured by HPLC and those measured by bioassay. However,
the poor sensitivity of the bioassay compared with the HPLC
method impaired its widespread use for the determination of the
intracellular antibiotic concentrations. Studies in our laboratories
have shown that a better fit of the extracellular data was obtained
when both techniques were applied to determine gentamicin.
Similar results were obtained comparing the results of the HPLC
assay and the bioassay of extracted samples from particles. How-
ever, the majority of data points fell significantly below the line
of unity and showed a poor overall fit to the data when fluori-
metric analysis and HPLC were compared. These results suggest
that the derivatization procedure underestimates the gentamicin
concentration of the analysed sample.
In addition, for gentamicin determination in animal tissues,
the chromatographic technique was the only assay able to quan-
tify gentamicin below 1 mg/mL, showing, once more, a clear
advantage over the other two techniques. Furthermore, since
the biological samples are known to be a complex matrix con-
taining proteins and other compounds, a specific method becomes
necessary.
In summary, we have developed an HPLC-MS method
adequate for determining gentamicin in biological samples and
pharmaceutical preparations. In contrast to other procedures, the
developed technique is rapid and precise and ensures high spe-
cificity, being a very attractive alternative to the microbiological
assays employed today.
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